Tracy SaxtonManaging Director at Dolby Family Ventures
Tracy joined Dolby Family Ventures in 2020 from Frazier Healthcare Partners, where she served as an adviser to the fund as well as founding CEO of an emerging precision oncology company. Tracy previously held investment positions with Pivotal bioVenture Partners, Roche Venture Fund (RVF) and SV Life Sciences Advisers (SVLSA), where she focused on the biopharmaceutical sector. Tracy currently serves on the Board of Therini Bio and Lengo Therapeutics, previously she served on the Board of companies including Vaxcyte (PCVX), Millendo Therapeutics (MLND), Mission Therapeutics and Purigen BioSystems, and she led the first institutional round of financing for Black Diamond Therapeutics (BDTX). Tracy previously held operating positions at Tularik (acquired by Amgen), Threshold Pharmaceuticals and Convelo Therapeutics. At Convelo, she was responsible for driving finance and business development which resulted in a collaboration and option to acquire transaction with Genentech/Roche. She began her career as a drug discovery scientist and moved to leadership roles in Regulatory Affairs, Project Management and Business Development.
Tracy earned her PhD in Medical Genetics from the University of Toronto, her MBA from Columbia University, and she was a Damon Runyon-Walter Winchell Cancer Fund fellow at University of California, San Francisco. She is also a Kauffman Fellow.